A carregar...
The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma
The prognosis of esophageal cancers is poor and novel approaches are urgently needed. Despite improvements in outcomes with transtuzumab and ramucirumab, these improvements added an average of only 2 to 3 months with a median overall survival reported to be around 1 year. Comprehensive genomic seque...
Na minha lista:
| Publicado no: | J Clin Med |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5126797/ https://ncbi.nlm.nih.gov/pubmed/27854242 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm5110100 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|